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Abstract—Endothelial dysfunction and low-grade inflammation are associated with cardiovascular disease. Arterial
stiffening plays an important role in cardiovascular disease and, thus, may be a mechanism through which endothelial
dysfunction and/or low-grade inflammation lead to cardiovascular disease. We investigated the associations between, on the
one hand, biomarkers of endothelial dysfunction (soluble endothelial selectin, thrombomodulin, and both vascular and
intercellular adhesion molecules 1 and von Willebrand factor) and of low-grade inflammation (C-reactive protein, serum
amyloid A, interleukin 6, interleukin 8, tumor necrosis factor- and, soluble intercellular adhesion molecule 1) and, on the
other hand, arterial stiffness over a 6-year period, in 293 healthy adults (155 women). Biomarkers were combined into mean
z scores. Carotid, femoral, and brachial arterial stiffness and carotid-femoral pulse wave velocity were determined by
ultrasonography. Measurements were obtained when individuals were 36 and 42 years of age. Associations were analyzed
with generalized estimating equation and adjusted for sex, height, and mean arterial pressure. The endothelial dysfunction z
score was inversely associated with femoral distensibility (:0.51 [95% CI:0.95 to0.06]) and compliance coefficients
(: 0.041 [95% CI: 0.076 to 0.006]) but not with carotid or brachial stiffness or carotid-femoral pulse wave velocity.
The low-grade inflammation z score was inversely associated with femoral distensibility (: 0.51 [95% CI: 0.95 to
0.07]) and compliance coefficients (:0.050 [95% CI:0.084 to0.016]) and with carotid distensibility coefficient (:
0.910 [95% CI: 1.810 to 0.008]) but not with brachial stiffness or carotid-femoral pulse wave velocity. Biomarkers of
endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness. This provides evidence that
arterial stiffening may be a mechanism through which endothelial dysfunction and low-grade inflammation lead to
cardiovascular disease. (Hypertension. 2011;58:588-595.) ● Online Data Supplement
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From observational studies,1–5 it has become increasinglyclear that biomarkers of endothelial dysfunction and
low-grade inflammation are closely associated with (incident)
cardiovascular disease. In part, these associations can be
explained by the fact that endothelial dysfunction and low-
grade inflammation play key roles in atherothrombosis.6
However, other mechanisms may also be important. In this
respect, arterial stiffening may constitute one such mecha-
nism. First, greater arterial stiffness has been shown to be
independently associated with cardiovascular morbidity and
mortality.7,8 Second, endothelial dysfunction and low-grade
inflammation affect the composition of the subendothelial
matrix, which is an important determinant of arterial
stiffness.9
Indeed, the association between biomarkers of endothelial
dysfunction and low-grade inflammation and greater arterial
stiffness is receiving increasing attention.10,11 However, pre-
vious studies on this topic were cross-sectional,10–26 and most
focused on either biomarkers of endothelial dysfunction24 or
low-grade inflammation12,16–23,25,26 and were done in middle-
aged or elderly populations.10,11,13–15,18–23,26 Importantly, en-
dothelial dysfunction and low-grade inflammation are closely
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linked and difficult to separate conceptually,27 and any
relationship with arterial stiffening may, therefore, be inter-
dependent. In addition, the process of arterial stiffening is
known to start at an early age.28
In view of the above, we hypothesize that the development
of biomarkers of endothelial dysfunction and low-grade
inflammation is associated with arterial stiffening in early
adulthood. Therefore, we have measured biomarkers of en-
dothelial dysfunction, low-grade inflammation, and arterial
stiffness twice in a population-based cohort, that is, for the
first time at the age of 36 years and for the second time at the
age of 42 years. We have investigated the 6-year longitudinal
associations between biomarkers of endothelial dysfunction
and low-grade inflammation, on the one hand, and stiffness
estimates of the carotid, femoral, and brachial arteries and of
the carotid-femoral segment, on the other, in apparently
healthy adults of the Amsterdam Growth and Health Longi-
tudinal Study.
Methods
Study Population
Data were derived from the Amsterdam Growth and Health Longi-
tudinal Study, an observational, longitudinal study that started in
1976 with a group of 698 boys and girls (details described else-
where).29 Briefly, its initial goal was to study the natural develop-
ment of the growth, health, and lifestyle of adolescents and to
investigate longitudinal relationships between biological and life-
style variables. The mean age of the individuals at the start of the
study was 13.10.8 years (meanSD). Since then, extensive
follow-up measurements have been done, and the cohort is still under
investigation. At each follow-up measurement, anthropometric
(body height, weight, and skinfolds), biological (blood pressure,
serum lipoprotein levels, and physical fitness), lifestyle (nutritional
habits, smoking behavior, and daily physical activity), and psycho-
logical variables were assessed.29
In addition, in blood samples of the individuals attending the 2000
and 2006 follow-up examinations (1 batch), 5 biomarkers of endo-
thelial dysfunction and 6 biomarkers of low-grade inflammation
were measured, and at both examinations arterial properties were
assessed by ultrasonography. At the first ultrasound examination,
377 individuals participated, and complete data on stiffness estimates
of the carotid, femoral, and brachial arteries were obtained in 373
individuals. From these, complete data on all 3 of the arteries were
obtained in 293 individuals during the follow-up ultrasound exami-
nation, all of whom had full data on biomarkers of endothelial
dysfunction and low-grade inflammation. The present study was,
therefore, conducted with these 293 individuals.
The study was approved by the local ethics committee of the Vrije
Universiteit University Medical Center, and all of the participants
gave their written informed consent.
Assessment of Endothelial Dysfunction and
Low-Grade Inflammation
Serum biomarkers of endothelial dysfunction (soluble intercellular
adhesion molecule 1 [sICAM-1], soluble vascular cell adhesion mole-
cule 1, soluble endothelial selectin, and soluble thrombomodulin), and
of low-grade inflammation (C-reactive protein [CRP], serum amyloid
A, interleukin 6, interleukin 8, tumor necrosis factor-, and sICAM-1)
were assessed by an electrochemiluminescence detection system using
multiarray technology (SECTOR Imager 2400, Meso Scale Discovery),
as described elsewhere30 (please see the online Data Supplement at
http://hyper.ahajournals.org). In addition, a plasma biomarker of endo-
thelial dysfunction (von Willebrand factor) was determined in citrated
plasma by means of ELISA, as described elsewhere30 (please see the
online Data Supplement).
Arterial Stiffness
We assessed local arterial stiffness of the carotid, femoral, and
brachial arteries and central arterial stiffness (the carotid-femoral
pulse wave velocity)31,32 (please see the online Data Supplement).
Other Measurements
Weight, height, body mass index, heart rate, and blood pressure were
determined according to international standards, and smoking behav-
ior was assessed by questionnaire as described previously.29,31 Total
and high-density lipoprotein cholesterol, triglycerides, and glycohe-
moglobin were determined as described previously.29,31 Hyperten-
sion was defined as a systolic blood pressure 140 mm Hg, and/or
a diastolic blood pressure 90 mm Hg, and/or treatment for
hypertension.
Statistical Analyses
All of the analyses were performed with SPSS (version 15, SPSS).
Variables with a skewed distribution (CRP, serum amyloid A,
interleukin 6, and triglycerides) were transformed using a natural
logarithm (ln). Overall z scores were calculated for endothelial
dysfunction or low-grade inflammation (please see the online Data
Supplement). We used generalized estimating equations to examine
the associations between either the overall z score for endothelial
dysfunction or the overall z score for low-grade inflammation and
arterial stiffness over the 6-year study period. In these analyses an
exchangeable correlation structure was used. Generalized estimating
equation analysis is a method for longitudinal data analyses and takes
into account the correlation of repeated measurements within indi-
viduals over time.33
First, we investigated the associations between the overall z scores
for either endothelial dysfunction or low-grade inflammation on the
one hand and arterial stiffness estimates on the other with adjust-
ments for sex, height, and mean arterial pressure. Second, the
analyses were repeated with mutual adjustments for the overall z
scores for either low-grade inflammation or endothelial dysfunction.
Third, to gain further insight into which of the individual elements of
the stiffness formulas might have been primarily responsible for any
relationships between endothelial dysfunction or low-grade inflam-
mation and arterial stiffness estimates, the analyses were repeated
with the individual elements of the stiffness formulas (diameter,
distension, pulse pressure, and intima-media thickness) as dependent
variables.
Data are presented as mean (SD) or median (interquartile
range) for skewed variables and regression coefficients () with
their 95% CIs. A 2-sided P value 0.05 was considered statisti-
cally significant.
Results
Table 1 shows the general characteristics, the biomarker
concentrations, and the stiffness estimates of the study
population. Systolic blood pressure remained stable
(116 mm Hg), diastolic blood pressure increased
(5.5 mm Hg), pulse pressure decreased (5.6 mm Hg), and
heart rate decreased (8.9 bpm) during the 6-year follow-up.
Biomarkers of low-grade inflammation remained fairly stable
over 6-year follow-up, except for a decrease in tumor necrosis
factor-. Biomarkers of endothelial dysfunction remained
stable or increased over 6-year follow-up, except for a
decrease in soluble endothelial selectin. Pulse pressure and
femoral and brachial artery stiffness decreased during 6-year
follow-up. Nevertheless, carotid artery stiffness increased
(for distensibility coefficient [DC]: 1.00*103/kPa; for
Young elastic modulus: 0.025 *103/kPa) during the 6-year
follow-up.
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Table 1. Characteristics of the Study Population
Variables 2000 2006 P
Age, y 36.60.6 42.60.6 0.001
Women, % 52.9 52.9 . . .
Smoker, % 64, 21.9 45, 15.4 0.001
Systolic blood pressure, mm Hg 116.311.7 116.214.4 0.858
Diastolic blood pressure, mm Hg 64.97.2 70.48.1 0.001
Pulse pressure, mm Hg 51.46.5 45.89.0 0.001
Mean arterial pressure, mm Hg 82.18.7 85.19.9 0.001
Prevalence of hypertension, % 5.1 9.6 0.015
Heart rate, bpm 70.511.4 61.69.0 0.001
Body height, cm 177.09.2 177.49.0 0.001
Body weight, kg 75.812.7 77.913.7 0.001
Body mass index, kg/m2 24.13.2 24.73.6 0.001
Total cholesterol, mmol/L 5.00.9 5.00.8 0.315
High density lipoprotein cholesterol, mmol/L 1.40.4 1.70.4 0.001
Triglycerides, mmol/L 1.0 (0.8 to 1.5) 1.0 (0.7 to 1.4) 0.018
HbA1c, % 5.20.4 5.40.4 0.001
Biomarkers
C-reactive protein, mg/L 0.8 (0.3 to 2.0) 0.8 (0.3 to 1.8) 0.946
Serum amyloid A, mg/L 1.2 (0.7 to 2.2) 1.3 (0.7 to 2.3) 0.099
Interleukin 6, ng/L 2.3 (1.7 to 3.7) 2.4 (1.8 to 3.7) 0.664
Interleukin 8, ng/L 9.23.4 9.54.1 0.190
Tumor necrosis factor-, ng/L 9.33.4 9.03.3 0.006
Soluble intercellular adhesion molecule 1, g/L 203.352.4 200.341.2 0.142
Soluble vascular cellular adhesion molecule 1, g/L 332.881.2 333.969.2 0.767
Soluble endothelial selectin, g/L 10.54.7 10.14.6 0.010
Soluble thrombomodulin, g/L 2.470.66 2.530.62 0.023
von Willebrand factor, % 102.540.0 112.842.4 0.001
Carotid artery
Distensibility coefficient, 103/kPa 26.76.1 25.77.2 0.014
Compliance coefficient, mm2/kPa 1.00.3 1.00.3 0.143
Young elastic modulus, 103/kPa 0.440.13 0.470.16 0.007
Diameter, mm 6.90.6 7.10.7 0.001
Distension, mm 0.60.1 0.50.1 0.001
Pulse pressure, mm Hg 51.37.1 45.99.4 0.001
Intima-media thickness, mm 0.620.10 0.660.12 0.001
Femoral artery
Distensibility coefficient, 103/kPa 7.13.7 8.34.5 0.001
Compliance coefficient, mm2/kPa 0.510.24 0.630.33 0.001
Diameter, mm 9.81.3 10.01.5 0.001
Distension, mm 0.220.10 0.230.10 0.149
Pulse pressure, mm Hg 51.47.2 46.59.8 0.001
Brachial artery
Distensibility coefficient, 103/kPa 14.69.2 17.611.2 0.001
Compliance coefficient, mm2/kPa 0.170.09 0.210.11 0.001
Diameter, mm 4.00.7 4.00.7 0.187
Distension, mm 0.180.09 0.190.10 0.205
Pulse pressure, mm Hg 51.77.2 45.09.5 0.001
Central arterial stiffness
Pulse wave velocity, m/s 7.71.6* 8.31.6† 0.001
Data are reported as meanSD, median (interquartile range), or percentage, as appropriate; P value, paired t test or
McNemar test, as appropriate; n293.
*n241.
†n292.
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Endothelial Dysfunction, Low-Grade
Inflammation, and Arterial Stiffness
The endothelial dysfunction overall z score was inversely
associated with the femoral artery DC (: 0.51 [95% CI:
0.95 to 0.06]; P0.025) and compliance coefficient (CC;
: 0.041 [95% CI: 0.076 to 0.006]; P0.020) after
adjustment for sex, height, and mean arterial pressure,
whereas it was not associated with carotid or brachial artery
stiffness (Table 2, model 1). Additional adjustment for the
low-grade inflammation overall z score decreased the regres-
sion coefficient () for the femoral artery DC by 32% and for
the femoral artery CC by 46% (Table 2, model 2). In addition,
the endothelial dysfunction overall z score was not associated
with carotid-femoral pulse wave velocity after adjustment for
sex, height, and mean arterial pressure (: 0.001 [95% CI:
0.22 to 0.22]; P0.994).
The low-grade inflammation overall z score was inversely
associated with the carotid artery DC (: 0.91 [95% CI:
1.81 to 0.008]; P0.048), femoral artery DC (: 0.51
[95% CI: 0.95 to 0.07]; P0.024), and CC (: 0.050
[95% CI: 0.084 to 0.016]; P0.004) after adjustment for
sex, height, and mean arterial pressure, whereas it was not
associated with carotid artery CC, Young elastic modulus, or
brachial artery stiffness (Table 2, model 1). Additional
adjustment for the endothelial dysfunction overall z score
decreased the regression coefficient () for the femoral artery
DC by 47% and for the femoral artery CC by 24%, whereas
the result for the carotid artery DC did not materially change
(Table 2, model 2). In addition, the low-grade inflammation
overall z score was not associated with carotid-femoral pulse
wave velocity after adjustment for sex, height, and mean
arterial pressure (: 0.074 [95% CI: 0.37 to 0.24];
P0.626).
Endothelial Dysfunction, Low-Grade
Inflammation, and Arterial Diameter, Distension,
Pulse Pressure, and Intima-Media Thickness
The inverse associations between the endothelial dysfunction
overall z score and the femoral artery DC and CC and the
low-grade inflammation overall z score and the femoral artery
DC and CC were primarily driven through inverse associa-
tions with femoral artery distension (for endothelial dysfunc-
tion: : 0.013 [95% CI: 0.025 to 0.001], P0.029; for
low-grade inflammation: : 0.015 [95% CI: 0.027 to
0.004], P0.010; please see the online Data Supplement
for Table S1). In contrast, the inverse association between the
low-grade inflammation overall z score and the carotid artery
DC was not primarily driven through any of the elements of
the stiffness formulas (Table S1).
Additional Analyses
Additional adjustment for age (the age range by design being
extremely narrow), smoking behavior, total and high-density
lipoprotein cholesterol, and hypertension did not materially
change the associations, whereas adjustment for weight did
attenuate the regression coefficients with 50% (Table S2).
None of the individuals had diabetes mellitus.
Table 2. Longitudinal Associations Between, on the One Hand, Endothelial Dysfunction and Low-Grade Inflammation Z Scores
During 6-y Follow-Up and, on the Other Hand, Arterial Stiffness Indices During 6-y Follow-Up (n293)
Variable
Carotid Artery Femoral Artery Brachial Artery
 95% CI P  95% CI P  95% CI P
Endothelial dysfunction
Distensibility coefficient
1: sex, height, MAP 0.19 1.02; 0.64 0.656 0.51 0.95;0.06 0.025 0.94 2.26; 0.39 0.165
2: 1low-grade inflammation z score 0.38 0.51; 1.27 0.402 0.34 0.89; 0.20 0.219 1.46 3.15; 0.24 0.092
Compliance coefficient
1: sex, height, MAP 0.012 0.049; 0.026 0.539 0.041 0.076;0.006 0.020 0.009 0.023; 0.004 0.163
2: 1low-grade inflammation z score 0.001 0.042; 0.041 0.972 0.022 0.065; 0.021 0.322 0.017 0.034; 0.001 0.058
Young elastic modulus
1: sex, height, MAP 0.001 0.020; 0.018 0.919 . . . . . . . . . . . . . . . . . .
2: 1low-grade inflammation z score 0.005 0.028; 0.017 0.636 . . . . . . . . . . . . . . . . . .
Low-grade inflammation
Distensibility coefficient
1: sex, height, MAP 0.91 1.81;0.008 0.048 0.51 0.95;0.07 0.024 0.19 1.11; 1.49 0.777
2: 1endothelial dysfunction z score 1.12 2.14;0.11 0.031 0.32 0.86; 0.22 0.247 0.99 0.64; 2.62 0.232
Compliance coefficient
1: sex, height, MAP 0.022 0.061; 0.018 0.288 0.050 0.084;0.016 0.004 0.005 0.008; 0.017 0.480
2: 1endothelial dysfunction z score 0.021 0.066; 0.023 0.353 0.038 0.080; 0.004 0.075 0.014 0.002; 0.030 0.092
Young elastic modulus
1: sex, height, MAP 0.006 0.013; 0.024 0.556 . . . . . . . . . . . . . . . . . .
2: 1endothelial dysfunction z score 0.009 0.013; 0.030 0.430 . . . . . . . . . . . . . . . . . .
 indicates longitudinal regression coefficients that express the relationships between the longitudinal development of endothelial dysfunction and low-grade
inflammation, on the one hand, and the longitudinal development of arterial stiffness on the other; 95% CI, 95% CIs and P value; MAP, mean arterial pressure.
van Bussel et al Endothelium, Inflammation, and Arterial Stiffness 591
In the analyses for the individual elements of the low-grade
inflammation z score, the results showed that ln serum
amyloid A and lnCRP were the strongest determinants of the
carotid artery DC (Figure A), whereas sICAM-1 and ln
interleukin 6 were the strongest determinants of the femoral
artery DC (Figure B) and sICAM-1 and lnCRP were the
strongest determinants for the femoral artery CC (Figure C).
For the endothelial dysfunction z score, sICAM-1 and soluble
endothelial selectin were the strongest determinants for the
femoral artery DC (Figure B) and CC (Figure C).
To investigate whether the longitudinal associations (by
generalized estimating equation) were primarily determined
by the between- or the within-subject associations over the
6-year study period, we calculated changes (ie, within-
subject) in the endothelial dysfunction overall z score, the
low-grade inflammation overall z score, and the arterial
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Biomarkers and Arterial Stiffness
Figure. Bars are regression coefficients that indi-
cate the associations between either the endothe-
lial dysfunction z score (ED), or the low-grade
inflammation (LGI) z score or each of the individual
biomarker z scores and the carotid distensibility
coefficient (A), the femoral distensibility coefficient
(B), and the femoral compliance coefficient (C)
over the 6-year study period. Whiskers indicate
the 95% CIs. All of the results are adjusted for
sex, height, and mean arterial pressure. sICAM-1
indicates soluble intercellular adhesion molecule 1;
sVCAM-1, soluble vascular cell adhesion molecule
1; sE-selectin, soluble endothelial selectin; sTM,
soluble thrombomodulin; vWf, von Willebrand fac-
tor; CRP, C-reactive protein; SAA, serum amyloid
A; IL-6, interleukin 6; IL-8, interleukin 8; TNF-,
tumor necrosis factor-; LN, log normalized.
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stiffness estimates. Then, we reanalyzed the data with the use
of linear regression analyses. Changes in the endothelial
dysfunction overall z score or in the low-grade inflammation
overall z score were not associated with changes in arterial
stiffness estimates (data not shown). This suggests that the
reported associations were primarily determined by the
between-subject associations over the 6-year study period.
Discussion
The present investigation is the first to prospectively evaluate,
in apparently healthy adults, the relationship between the
development of an extensive array of biomarkers of endothe-
lial dysfunction and low-grade inflammation on the one hand
and arterial stiffness on the other. The study had 3 main
findings. First, biomarker scores for endothelial dysfunction
and low-grade inflammation were associated with greater
arterial stiffness over a 6-year period. The biomarker score
for endothelial dysfunction was associated with greater fem-
oral artery stiffness, whereas the biomarker score for low-
grade inflammation was associated with both greater carotid
and femoral artery stiffness. However, both the biomarker
scores for endothelial dysfunction and low-grade inflamma-
tion were not associated with stiffness of the carotid-femoral
segment. Endothelial dysfunction and/or low-grade inflam-
mation may, thus, affect arterial stiffening in a way that
depends on the arterial territory under study.34 Second,
mutual adjustment for either the biomarker score for low-
grade inflammation or endothelial dysfunction showed that
the associations between either the biomarker score for
endothelial dysfunction or low-grade inflammation with fem-
oral artery stiffness were interdependent. Finally, the associ-
ations between each of the biomarker scores and greater
femoral artery stiffness were primarily driven through de-
creased distension, whereas the association between low-
grade inflammation and greater carotid stiffness was not
primarily driven through any of the arterial parameters.
The endothelium has many functions and is itself hetero-
geneous.35,36 The concept of endothelial dysfunction, there-
fore, has many dimensions.37 von Willebrand factor, soluble
vascular cell adhesion molecule 1, soluble endothelial selec-
tin, soluble thrombomodulin, and sICAM-1 are all synthe-
sized by endothelial cells,6,35,36 and higher concentrations of
these biomarkers are associated with (incident) cardiovascu-
lar disease.1–5 Consequently, it is plausible to assume that
higher circulating concentrations of these biomarkers reflect
greater dysfunction.
A limitation of this study is that a measure of NO-mediated
dilation, which represents an important function of the
endothelium,35–37 was not available. Nevertheless, both bio-
markers of the endothelium and NO-mediated dilation (eg,
flow-mediated dilation) have been associated with (incident)
cardiovascular disease.1–5,38
Furthermore, endothelial dysfunction is closely linked with
low-grade inflammation and, therefore, these concepts are
difficult to separate.27 We, indeed, show that the associations
with femoral artery stiffening are dependent on both endo-
thelial dysfunction and low-grade inflammation, whereas this
was not the case for carotid artery stiffening. This suggests
that endothelial dysfunction and low-grade inflammation
might affect arterial stiffening in concert or, independently,
dependent on the arterial territory under study.
The present investigation was comprehensive and had
advantages over previous ones, which investigated either
biomarkers of endothelial dysfunction24 or low-grade in-
flammation,12,16 –23,25,26 measured a less extensive array of
biomarkers of endothelial dysfunction and low-grade in-
flammation,10 –26 concerned middle-aged to elderly indi-
viduals,10,11,13–15,18 –23,26 targeted 1 type of artery only,10 –25
and were cross-sectional by design.10 –26
On aggregate, previous studies have shown higher CRP levels
to be associated with greater arterial stiffness of elastic,10–14,16–23
muscular,25 or both types of arteries26 and higher interleukin 6
levels to be associated with greater elastic arterial stiffness.11,15
Taken together, these studies10–23,25,26 and the present results
support the concept that low-grade inflammation may affect
arterial stiffness. In particular, we show that this process is
present even in young, apparently healthy adults.
With regard to biomarkers of endothelial dysfunction,
previous studies have shown heterogeneous results for von
Willebrand factor and sICAM-1, some reporting positive
associations with elastic arterial stiffness,15,24 whereas others
did not.11,13,14 We show that the overall endothelial dysfunc-
tion z score was significantly associated with femoral artery
stiffness (Figure B and C), whereas none of the individual
endothelial dysfunction biomarkers was, except for
sICAM-1. This may be explained by the fact that, in these
young, apparently healthy individuals, endothelial dysfunc-
tion may not be very far advanced and, therefore, only the
sum of endothelial dysfunction biomarkers reveals its asso-
ciation with greater arterial stiffness.
Endothelial dysfunction may influence arterial stiffening
by affecting vascular smooth muscle cell tone because of the
reduced availability of NO and the increased activity of
vasoconstrictor substances such as endothelin 19 and by
affecting the composition of the extracellular matrix.9 In
addition, inflammation may induce both functional and struc-
tural changes in the arterial wall via the increased production
of reactive oxygen species,39 which, in turn, triggers an
inflammatory process leading to the proliferation of smooth
muscle cells, the influx of leukocytes, and the production of
proinflammatory substances and chemoattractants.6 Our data
support the notion that both endothelial dysfunction and
low-grade inflammation may cause increased muscular artery
stiffness via similar pathophysiological pathways, as in the
femoral artery both endothelial dysfunction and low-grade
inflammation primarily appeared to affect arterial distension
(please see Figure S1). In contrast, only low-grade inflam-
mation affected (elastic) carotid artery stiffness, most likely
through a pathophysiological mechanism independent of
endothelial dysfunction and not specifically driven through
diameter, distension, pulse pressure, or intima-media thick-
ness. This suggests that low-grade inflammation may cause
increased arterial stiffness of elastic arteries by affecting
multiple elements of the vascular wall. These observations
particularly align with the notion that the atherosclerotic and
arteriosclerotic processes are, at least in part, inflammatory in
origin and that inflammatory changes may lead to an altered
matrix homeostasis (affecting vascular smooth muscle cells
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and matrix proteins), which, in turn, leads to a decrease in
(femoral) distension. Taken together, the above suggests that
endothelial dysfunction and low-grade inflammation may
affect arterial stiffness of either muscular or elastic arteries
differently. This might explain why endothelial dysfunction
and low-grade inflammation were not associated with
carotid-femoral pulse wave velocity, because the carotid-
femoral segment includes both elastic and muscular arterial
components. Alternatively, the adults investigated were
young and did not have central arterial stiffening, which
typically occurs after the age of 60 years.7
Additional adjustment for potential confounders did not
materially change the results, whereas adjustment for body
weight attenuated the associations between biomarkers of
endothelial dysfunction or low-grade inflammation and arte-
rial stiffness. However, it is questionable whether body
weight should be seen as a true confounder in this relation-
ship. It is biologically more plausible that body weight is part
of the causal pathway, that is, body weight influences
biomarkers of endothelial dysfunction and low-grade inflam-
mation,40 and these influence arterial stiffening.9
Finally, the time frame in which endothelial dysfunction or
low-grade inflammation have their possible impacts on arte-
rial stiffness is unknown and might differ from the 6-year
period of the present investigation. (This might explain why
changes in biomarkers of endothelial dysfunction or low-
grade inflammation did not parallel changes in arterial stiff-
ness.) The question remains for what period a person should
have endothelial dysfunction or low-grade inflammation be-
fore it affects the vasculature. In any case, our results may
suggest that any inflammatory changes that have led to
arterial stiffening have already occurred before the age of 36
years.
The present investigation had some limitations. First,
intrinsic to an overall z score is the assumption that each
biomarker in the z score carries similar weight. This might
have caused us to underestimate the reported associations
because of error attributed to a mathematical approach that
might not optimally reflect pathophysiology. Second, the
increase in diastolic blood pressure of 6 mm Hg and the
practically unchanged levels of systolic blood pressure be-
tween the ages of 36 and 42 years in this study population led
to a decrease in pulse pressure. Although this may seem
“unexpected,” increases in pulse pressure with ageing are
often observed after the fifth or sixth decades of life as a
consequence of arterial stiffening.7 In addition, these changes
were in line with previous life course trends in changes of the
2 blood pressure components in this cohort, showing steeper
increases in (sitting) diastolic (0.6 mm Hg/y) than systolic
blood pressure (0.2 mm Hg/y) between late adolescence (age
15 years) and age 36 years (data not shown). Still, because
different blood pressure devices were used during the 2
measurement periods, it is possible that diastolic blood
pressure data from the year 2000 may have been underesti-
mated as compared with the 2006 data. As a consequence, at
the population level, pulse pressure and all arterial stiffness
estimates are most likely underestimated in 2006 as compared
with 2000. Nevertheless, a systematic underestimation of
stiffness does not materially change the reported associations.
Third, on the population level, heart rate was higher in 2000
as compared with 2006. This might be explained by the fact
that the ultrasound examination was introduced for the first
time in 2000, and, at the second ultrasound examination,
individuals might have been more relaxed because they knew
what was going to happen. Because a (patho)physiological
explanation is not readily at hand, such an effect might
explain the difference in heart rate. Again, however, this
would not be expected to affect the associations observed.
Fourth, renal function was only determined in 2006. Al-
though additional adjustment did not materially change our
results, the present study, therefore, can only partly exclude a
role for renal function in the reported associations. Finally,
our data were obtained in a young, white population, and,
therefore, inferences to older individuals and (or) other
ethnicities should be made with caution.
Perspectives
Both scores of biomarkers for endothelial dysfunction and
low-grade inflammation are associated with greater arterial
stiffness in apparently healthy adults over a 6-year period.
This suggests that arterial stiffness may be a mechanism
through which endothelial dysfunction and low-grade inflam-
mation lead to cardiovascular disease. In addition, the results
showed that, early in the development of arterial stiffening,
endothelial dysfunction and low-grade inflammation act dif-
ferentially along the arterial tree. These data may help us to
understand the pathophysiology of early arterial stiffening
and may provide potential targets for intervention.
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